Rizatriptan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Rizatriptan
Rizatriptan.svg
Systematic (IUPAC) name
N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
Clinical data
Trade names Maxalt
AHFS/Drugs.com monograph
MedlinePlus a601109
Pregnancy cat. B1 (Au), C (U.S.)
Legal status Prescription only
Routes Oral
Pharmacokinetic data
Bioavailability 45%
Protein binding 14%
Metabolism by monoamine oxidase
Half-life 2–3 hours
Excretion 82% urine; 12% faeces
Identifiers
CAS number 145202-66-0 YesY
ATC code N02CC04
PubChem CID 5078
IUPHAR ligand 51
DrugBank DB00953
ChemSpider 4900 YesY
UNII WR978S7QHH YesY
KEGG D00675 N
ChEBI CHEBI:48273 YesY
ChEMBL CHEMBL905 YesY
Chemical data
Formula C15H19N5 
Mol. mass 269.345 g/mol
 N (what is this?)  (verify)


Rizatriptan (trade name Maxalt) is a 5-HT1 agonist triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.

Rizatriptan is available only by prescription in Australia, Finland, the United States, Canada and New Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom, Italy (as Rizaliv), Israel (as Rizalt), The Netherlands, Croatia and Spain (as Maxalt)

Use[edit]

Rizatriptan is used to treat acute migraine attacks with or without aura. It does not prevent future migraine attacks.

Contraindications[edit]

Adverse effects[edit]

References[edit]

External links[edit]